BNF 82 New drug monographs: Glycopyrronium with formoterol fumarate, Formoterol fumarate with glycopyrronium and budesonide The interactions are displaying correctly when the interactions information is accessed directly via links from the Interactions section of the co-drug monographs in BNF and BNF for Children.

The cover image preview of BNF 84 (British National Formulary) September 2022 – March 2023 PDF Looks Something like this: Over the last year, we have undertaken research to understand how we could ensure that specialist drug content in BNF Publications is aligned with the stated scope within the preface, and with the primary use case of the BNF. Analytics around the use of BNF Publications’ content confirmed that specialist drug content is accessed much less frequently than drug content for non-specialist use. User research supported the analytics, and showed that those users who did access specialist content were most commonly looking at safety information, such as contra-indications, interactions, and side-effects. Ibrutinib (Imbruvica®): new risk minimisation measures, including dose modification recommendations, due to the increased risk for serious cardiac events Important safety updates: Amiodarone hydrochloride, COVID-19 antivirals, Chloroquine and hydroxychloroquine sulfate, Haloperidol, Metformin hydrochloride, Pregabalin, Potassium permanganateA "file MD5" is a hash that gets computed from the file contents, and is reasonably unique based on that content. All shadow libraries that we have indexed on here primarily use MD5s to identify files. New and updated treatment summaries: Genital system infections, antibacterial therapy, Venous thromboembolism Blood Results in Clinical Practice: A Practical Guide to Interpreting Blood Test Results - 2nd ed. (2019) Management of iron deficiency anaemia, including update to oral iron dosing and monitoring based on British Society of Gastroenterology guidelines

BNF 78 New drug monographs: Ertugliflozin (Steglatro), Insulin glargine with lixisenatide (Suliqua), Stiripentol (Diacomit) And for research and study, we maintain a regularly updated list of open-access journals. Accessing the e-Library Already a member?Learn how treatment guidance from Palliative Care Formulary can support health professionals to manage cancer-related neuropathic pain.

The results of this research have enabled us to critically review the information that should be included within specialist drug monographs. “Specialist drug” monographs will contain less detail than a regular monograph within BNF Publications, in a consistent format. A “specialist” monograph will continue to include information to support patient safety and non-specialist patient care (such as important safety information, interactions, side-effects, and contra-indications), but it will not contain information which is within the remit of specialist care (such as doses, and directions for administration). The current level of additional prescribing information has been retained for drug monographs that have a mix of specialist and non-specialist uses (such as methotrexate that is used for both malignancy and rheumatological conditions).

Physicochemical Principles of Pharmacy in Manufacture, Formulation and Clinical Use - 6th ed. (2016)

Livtencity® [maribavir] for cytomegalovirus disease in recipients of haematopoietic stem cell transplant or solid organ transplant We may be able to source and supply a paper copy in exceptional circumstances, from surplus BNFs distributed to other parts of the NHS. Please register your interest in receiving a copy via the online form at: https://www.snapsurveys.com/wh/s.asp?k=153553886772 Pharmaceutical Preformulation and Formulation: a Practical Guide from Candidate Drug Selection to Commercial Dosage Form - 2nd ed. (2009)

BNF 84 New drug monographs: Icosapent ethyl (▼Vazkepa), Baloxavir marboxil (▼Xofluza), Herpes-zoster vaccine [recombinant, adjuvanted] (▼Shingrix) Joint Formulary Committee (2021) 'Paracetamol', in British National Formulary. Available at: https://www-medicinescomplete-com.apollo.worc.ac.uk/#/content/bnf/_970446495(Accessed: 21July2022). The BNF is jointly published by the Royal Pharmaceutical Society and BMJ. BNF is published in print twice a year and interim updates are issued and published monthly in the digital versions. The following summary provides a brief description of some recent key changes that have been made to BNF content. The BNF is authored by the Joint Formulary Committee and you can access it via our Medicines Complete subscription. Updated monographs or dose changes: Dapagliflozin (Forxiga), Vaginal oestrogens, Chloral hydrate, Calcipotriol with betamethasone (Enstilar)